Supplementary announcement on discloseable transaction
Filed with HKEX · Stock code 9966 · · 1 page · English
Summary by 6ix AI
Alphamab Oncology has issued a supplementary announcement regarding a discloseable transaction involving the exercise of a warrant to subscribe for preferred stock of Pathos AI, Inc. The announcement clarifies that the ultimate beneficial owner of Pathos AI is Mr. Eric Paul Lefkofsky, who is the founder and chairman of the company. All other information from the previous announcement remains unchanged.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Alphamab Oncology
- Voluntary announcement - first patient dosed in phase III clinical study of JSKN033 monotherapy for the treatment of cervical cancer
- Grant of award shares under the restricted share award scheme
- Voluntary announcement - latest research updates of JSKN003 presented at the 2026 ESMO congress
- Voluntary announcement - results of a phase I/II clinical study of JSKN033 in patients with CC following failure of standard treatment were presented at the 2026 esmo congress as a rapid oral presentation
- Voluntary announcement - latest research results of two phase III clinical studies of anbenitamab (KN026) were presented at the 2026 ESMO Congress as lba oral presentations
Later from Alphamab Oncology
- Voluntary announcement - IND approval by the FDA for a phase I clinical study of JSKN021
- Next Day Disclosure Return
Follow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology